文献速递心脑血管急症

药物洗脱支架植入术后合并或不合并糖尿病患者短期与长期双联抗血小板治疗的比较:基于随机试验个体参与者数据的系统评价与Meta分析

Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials.
PubMed 文献 · BMJ · 2016-11-03
一句话结论在药物洗脱支架植入术后患者中,无论是否合并糖尿病,与短期(≤6个月)DAPT相比,长期(12个月)DAPT未降低MACE风险,但增加出血风险。

该研究为个体参与者数据Meta分析,纳入6项比较药物洗脱支架植入术后DAPT时长的随机对照试验,共11473例患者,其中3681例(32.1%)合并糖尿病。主要终点为1年MACE(心源性死亡、心肌梗死或明确/可能的支架血栓)。结果显示,糖尿病是MACE的独立预测因素(HR 2.30,95%CI 1.01-5.27;P=0.048)。与短期DAPT相比,长期DAPT在合并糖尿病(HR 1.05,95%CI 0.62-1.76;P=0.86)和不合并糖尿病(HR 0.97,95%CI 0.67-1.39;P=0.85)患者中均未降低MACE风险(交互作用P=0.33)。长期DAPT在合并糖尿病患者中降低明确/可能的支架血栓风险(HR 0.26,95%CI 0.09-0.80;P=0.02),在不合并糖尿病患者中未见降低(HR 1.42,95%CI 0.68-2.98;P=0.35),交互作用P=0.04。长期DAPT增加大出血或小出血风险,与糖尿病状态无关(交互作用P=0.37)。

要点

  • 在药物洗脱支架植入术后患者中,无论是否合并糖尿病,长期DAPT(12个月)与短期DAPT(≤6个月)相比未降低1年MACE风险(合并糖尿病HR 1.05,95%CI 0.62-1.76;不合并糖尿病HR 0.97,95%CI 0.67-1.39)。
  • 长期DAPT增加大出血或小出血风险,且与糖尿病状态无关(交互作用P=0.37)。
  • 合并糖尿病患者中,长期DAPT降低明确/可能的支架血栓风险(HR 0.26,95%CI 0.09-0.80;P=0.02),不合并糖尿病患者中未见降低(HR 1.42,95%CI 0.68-2.98;P=0.35),交互作用P=0.04。
  • 糖尿病是药物洗脱支架植入术后MACE的独立预测因素(HR 2.30,95%CI 1.01-5.27;P=0.048)。
  • 长期DAPT与短期DAPT的心肌梗死风险无显著差异(合并糖尿病HR 0.95,95%CI 0.58-1.54;不合并糖尿病HR 1.15,95%CI 0.68-1.94;交互作用P=0.84)。

适用人群与场景

  • 药物洗脱支架植入术后的患者,合并或不合并糖尿病。
  • 纳入6项比较DAPT时长的随机对照试验的个体参与者数据,共11473例患者,其中3681例(32.1%)合并糖尿病,7708例(67.2%)不合并糖尿病,84例(0.7%)糖尿病信息缺失。
  • 合并糖尿病患者的平均年龄63.7岁(SD 9.9),不合并糖尿病患者的平均年龄62.8岁(SD 10.1)。

研究设计与关键结果

  • 研究设计:个体参与者数据Meta分析,纳入6项随机对照试验,比较药物洗脱支架植入术后短期DAPT(至多6个月)与长期DAPT(12个月)。
  • 主要终点:1年MACE(心源性死亡、心肌梗死或明确/可能的支架血栓),所有分析按意向治疗进行。
  • 糖尿病是MACE的独立预测因素(HR 2.30,95%CI 1.01-5.27;P=0.048)。
  • 长期DAPT与短期DAPT相比,合并糖尿病患者MACE风险无显著差异(HR 1.05,95%CI 0.62-1.76;P=0.86),不合并糖尿病患者也无显著差异(HR 0.97,95%CI 0.67-1.39;P=0.85),交互作用P=0.33。
  • 心肌梗死风险在两种DAPT方案间无显著差异:合并糖尿病HR 0.95(95%CI 0.58-1.54;P=0.82),不合并糖尿病HR 1.15(95%CI 0.68-1.94;P=0.60),交互作用P=0.84。
  • 明确/可能的支架血栓风险:合并糖尿病患者长期DAPT较低(HR 0.26,95%CI 0.09-0.80;P=0.02),不合并糖尿病患者无显著差异(HR 1.42,95%CI 0.68-2.98;P=0.35),交互作用P=0.04;里程碑分析显示两组均有获益趋势。
  • 长期DAPT增加大出血或小出血风险,与糖尿病状态无关(交互作用P=0.37)。

证据类型、等级与局限

  • 证据类型:基于6项随机对照试验个体参与者数据的系统评价与Meta分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在药物洗脱支架植入术后患者中,无论是否合并糖尿病,长期DAPT(12个月)与短期DAPT(≤6个月)相比未降低MACE风险,但增加出血风险,支持在临床决策中权衡缺血与出血风险。
  • 合并糖尿病患者中,长期DAPT可能降低明确/可能的支架血栓风险(HR 0.26,95%CI 0.09-0.80),但需结合出血风险个体化评估。
  • 糖尿病是药物洗脱支架植入术后MACE的独立预测因素(HR 2.30,95%CI 1.01-5.27),提示对该人群需加强危险因素管理。

指南或共识出处

  • Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials(BMJ)

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: To compare clinical outcomes between short term (up to 6 months) and long term (12 months) dual antiplatelet therapy (DAPT) after placement of a drug eluting stent in patients with and without diabetes.

DESIGN: Individual participant data meta-analysis. Cox proportional regression models stratified by trial were used to assess the impact of diabetes on outcomes.

DATA SOURCE: Medline, Embase, and Cochrane databases and proceedings of international meetings searched for randomised controlled trials comparing durations of DAPT after placement of a drug eluting stent. Individual patient data pooled from six DAPT trials.

PRIMARY OUTCOME: Primary study outcome was one year risk of major adverse cardiac events (MACE), defined as cardiac death, myocardial infarction, or definite/probable stent thrombosis. All analyses were conducted by intention to treat.

RESULTS: Six trials including 11 473 randomised patients were pooled. Of these patients, 3681 (32.1%) had diabetes and 7708 (67.2%) did not (mean age 63.7 (SD 9.9) and 62.8 (SD 10.1), respectively), and in 84 (0.7%) the information was missing. Diabetes was an independent predictor of MACE (hazard ratio 2.30, 95% confidence interval 1.01 to 5.27; P=0.048 At one year follow-up, long term DAPT was not associated with a decreased risk of MACE compared with short term DAPT in patients with (1.05, 0.62 to 1.76; P=0.86) or without (0.97, 0.67 to 1.39; P=0.85) diabetes (P=0.33 for interaction). The risk of myocardial infarction did not differ between the two DAPT regimens (0.95, 0.58 to 1.54; P=0.82; for those with diabetes and 1.15, 0.68 to 1.94; P=0.60; for those without diabetes (P=0.84 for interaction). There was a lower risk of definite/probable stent thrombosis with long term DAPT among patients with (0.26, 0.09 to 0.80; P=0.02) than without (1.42, 0.68 to 2.98; P=0.35) diabetes, with positive interaction testing (P=0.04 for interaction), although the landmark analysis showed a trend towards benefit in both groups. Long term DAPT was associated with higher rates of major or minor bleeding, irrespective of diabetes (P=0.37 for interaction).

CONCLUSIONS: Although the presence of diabetes emerged as an independent predictor of MACE after implantation of a drug eluting stent, compared with short term DAPT, long term DAPT did not reduce the risk of MACE but increased the risk of bleeding among patients with stents with and without diabetes.

来源:BMJ,查看原文。版权归原作者所有。

参考来源

  1. Gargiulo G, Windecker S, da Costa BR, et al. Short term versus long term dual antiplatelet therapy after implantation of drug eluting stent in patients with or without diabetes: systematic review and meta-analysis of individual participant data from randomised trials. BMJ. 2016. PMID: 27811064. doi:10.1136/bmj.i5483

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。